يعرض 1 - 10 نتائج من 91 نتيجة بحث عن '"Ciardiello F."', وقت الاستعلام: 1.13s تنقيح النتائج
  1. 1
    دورية أكاديمية
    1092P Clinical potential of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to first-line (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC)

    المؤلفون: Ciardiello, F.1 (AUTHOR), Feng, Z.2 (AUTHOR), Smith, N.R.3 (AUTHOR), Andric, Z.G.4 (AUTHOR), Shell, S.5 (AUTHOR), Yablonovitch, A.6 (AUTHOR), Guezel, G.7 (AUTHOR), Scheuenpflug, J.3 (AUTHOR)

    المصدر: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1050-S1051. 2p.

    مصطلحات موضوعية: *CIRCULATING tumor DNA, *LUNGS, *TUMORS

    النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    436TiP COLSTAR: Randomized, open-label, multicentre, phase III study comparing futuximab/modotuximab plus trifluridine/tipiracil to trifluridine/tipiracil in KRAS/NRAS and BRAF wild type (wt) metastatic colorectal cancer (mCRC) previously treated with both standard and anti-EGFR treatment

    المؤلفون: Ciardiello, F.1 (AUTHOR), Yoshino, T.2 (AUTHOR), Modest, D.P.3 (AUTHOR), Martin Fernandez, L.4 (AUTHOR), Roby, L.4 (AUTHOR), Fougeray, R.4 (AUTHOR), Lockhart, B.P.5 (AUTHOR), Tabernero, J.6 (AUTHOR)

    المصدر: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS733-S734. 2p.

    مصطلحات موضوعية: *COLORECTAL cancer, *BRAF genes, *METASTASIS

    النص الكامل

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.

    المؤلفون: Ciardiello, F.1 fortunato.ciardiello@unina2.it, Normanno, N.2, Martinelli, E.1, Troiani, T.1, Pisconti, S.3, Cardone, C.1, Nappi, A.1, Bordonaro, A. R.4, Rachiglio, M.2,5, Lambiase, M.2,5, Latiano, T. P.6, Modoni, G.3, Cordio, S.4, Giuliani, F.7, Biglietto, M.8, Montesarchio, V.9, Barone, C.10, Tonini, G.11, Cinieri, S.12, Febbraro, A.13

    المصدر: Annals of Oncology. Jun2016, Vol. 27 Issue 6, p1055-1061. 7p. 1 Diagram, 3 Graphs.

    مصطلحات موضوعية: *CETUXIMAB, *COLON cancer treatment, *METASTASIS, *CANCER chemotherapy, *EPIDERMAL growth factor receptors, *THERAPEUTICS

    النص الكامل

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

    المؤلفون: McLellan, B.1, Ciardiello, F.2 bmclella@montefiore.org, Lacouture, M. E.3, Segaert, S.4, Van Cutsem, E.4

    المصدر: Annals of Oncology. Oct2015, Vol. 26 Issue 10, p2017-2026. 10p. 1 Color Photograph, 1 Diagram, 4 Charts.

    مصطلحات موضوعية: *REGORAFENIB, *COLON cancer risk factors, *HAND-foot syndrome, *NATURAL selection, *THERAPEUTICS

    People: SUMNER, William Graham, 1840-1910

    النص الكامل

    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.

    المؤلفون: Ciardiello, F.1, Normanno, N.2, Maiello, E.3, Martinelli, E.1, Troiani, T.1, Pisconti, S.4, Giuliani, F.5, Barone, C.6, Cartenì, G.7, Rachiglio, A. M.2, Montesarchio, V.8, Tonini, G.9, Rizzi, D.5, Cinieri, S.10, Bordonaro, R.11, Febbraro, A.12, De Vita, F.1, Orditura, M.1, Fenizia, F.2, Lambiase, M.2

    المصدر: Annals of Oncology. Sep2014, Vol. 25 Issue 9, p1756-1761. 6p.

    مصطلحات موضوعية: *COLON cancer treatment, *EPIDERMAL growth factor receptors, *CETUXIMAB, *GENETIC mutation, *RANDOMIZED controlled trials

    النص الكامل

    أضف إلى المفضلة
  6. 6
    دورية أكاديمية
    Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).

    المؤلفون: Ciardiello, F.1, Arnold, D.2, Casali, P. G.3, Cervantes, A.4, Douillard, J.-Y.5, Eggermont, A.6, Eniu, A.7, McGregor, K.8, Peters, S.9, Piccart, M.10, Popescu, R.11, Van Cutsem, E.12, Zielinski, C.13, Stahel, R.14

    المصدر: Annals of Oncology. Sep2014, Vol. 25 Issue 9, p1673-1678. 6p.

    مصطلحات موضوعية: *DRUG delivery systems, *ONCOLOGY, *PHENOTYPES, *BIOMARKERS, *MEDICAL sciences

    النص الكامل

    أضف إلى المفضلة
  7. 7
    دورية أكاديمية
    Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

    المؤلفون: Tabernero, J.1, Ciardiello, F.2, Rivera, F.3, Rodriguez-Braun, E.4, Ramos, F. J.1, Martinelli, E.2, Vega-Villegas, M. E.3, Roselló, S.4, Liebscher, S.5, Kisker, O.6, Macarulla, T.1, Baselga, J.1, Cervantes, A.4

    المصدر: Annals of Oncology. Jul2010, Vol. 21 Issue 7, p1537-1545. 9p. 5 Charts, 1 Graph.

    مصطلحات موضوعية: *CETUXIMAB, *COLON cancer, *DRUG dosage, *PHARMACODYNAMICS, *PHARMACOKINETICS

    النص الكامل

    أضف إلى المفضلة
  8. 8
    دورية أكاديمية
    Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.

    المؤلفون: Ciardiello, F.1 fortunato.ciardiello@unina2.it, Troiani, T.1, Caputo, F.2, De Laurentiis, M.2, Tortora, G.2, Palmieri, G.2, De Vita, F.1, Diadema, M. R.1, Orditura, M.1, Colantuoni, G.3, Gridelli, C.3, Catalano, G.1, De Placido, S.2, Bianco, A. R.2

    المصدر: British Journal of Cancer. 6/5/2006, Vol. 94 Issue 11, p1604-1609. 6p. 3 Charts.

    مصطلحات موضوعية: *CANCER treatment, *EPIDERMAL growth factor, *TYROSINE, *CYTOKINES, *BREAST cancer, *SELECTIVE estrogen receptor modulators

    النص الكامل

    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs

    المؤلفون: Ciardiello, F.1 fortunatociardiello@yahoo.com, Tortora, Giampaolo2

    المصدر: European Journal of Cancer. Jul2003, Vol. 39 Issue 10, p1348. 7p.

    مصطلحات موضوعية: *CELL receptors, *CANCER treatment


    أضف إلى المفضلة
  10. 10
    دورية أكاديمية
    Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents.

    المؤلفون: Ciardiello, F.1

    المصدر: Drugs. Aug2000 Supplement, Vol. 60 Issue 2, p25-32. 8p.

    مصطلحات موضوعية: *EPIDERMAL growth factor, *PROTEIN-tyrosine kinases, *ENZYME inhibitors


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث